Chutes & Ladders: FDA names Pazdur to lead new cancer initiative

para

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) and we will feature it here at the end of each week.

FDA names Dr. Richard Pazdur to lead new cancer initiative

Imara

 

 

 

 

 

McArthur

 

 

 

 

FDA
Dr. Richard Pazdur was named interim head of the Oncology Center of Excellence.

The FDA’s cancer drug czar, Dr. Richard Pazdur, took the reins this week at the new Oncology Center of Excellence, serving as acting director in a push by the federal agency to coordinate resources and expedite oncology drug development. Pazdur’s appointment comes following an internal search, with FDA Director Robert Califf saying “I can think of no one more qualified to shepherd the agency into a new era of regulation over oncology products than the FDA’s own Dr. Richard Pazdur.” For nearly 20 years, Pazdur has led the FDA’s efforts in advancing cancer treatments, Califf added; the announcement comes the same month Pazdur lamented a “me-too” trend by biopharmas in oncology. He’ll serve on an interim basis at the center--part of Vice President Joe Biden’s “Moonshot” cancer initiative--while things get up and running. An FDA spokesperson said the regulator will complete a national search for a permanent head. Story | Release


Boehringer slashes 724 jobs off U.S. sales payroll to boost R&D spending. Story


Biotech

G&W Labs named Jay Galeota its president and COO. Release

> Kalytera tapped Dr. Stuart Silverman to serve as SVP of medical affairs. Release

Aratana Therapeutics appointed Brent Standridge as its chief operating officer. Release

> Maria Cantor joined uniQure as senior vice president of investor relations and communications. Release

CRO 

> Envigo selected Adrian Hardy as its next president and CEO. Release

Suggested Articles

ElevateBio raised $170 million to propel six programs into the clinic and get its centralized R&D and manufacturing hub up and running.

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

Regeneron's latest cholesterol fighter cut "bad" cholesterol in half for patients with a rare genetic disorder, including in hard-to-treat…